← Eichor
Study identifier: NCT05672043 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China

Condition: Medulloblastoma · Central Nervous System Tumor, Pediatric · Ependymoma  ·  Sponsor: Beijing Tiantan Hospital

PhaseN/A
Planned participants400
Who can joinAll sexes, 0 Years to 18 Years
Healthy volunteersNo

About this study

Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.

This description comes directly from the study's public registry record.

Talk to the study team

Tao Jiang, MD  ·  +8613501306106  ·  doctorjiangtt@163.com

Yahui Zhao, MD  ·  +8618519325917  ·  yahuii.zhao@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan HosiptalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05672043